Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

Revenues for Lupin Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 1.875000
forwardPE 21.804314
debtToEquity 31.500000
earningsGrowth 1.147000
revenueGrowth 0.142000
grossMargins 0.698680
operatingMargins 0.178660
trailingEps 71.720000
forwardEps 81.760000

LUPIN's current ratio is 1.875, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as LUPIN should not face any issues meeting its short-term liabilities with available resources.
Lupin Limited's Forward PE being in a good range indicates that the stock is valued appropriately based on its earnings. This suggests the stock is not overpriced and leaves room for growth, providing investors with an opportunity for potential appreciation in value.
Positive earnings and revenue growth for LUPIN point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
LUPIN's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting LUPIN to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

The stock price of Lupin Limited has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


The analysts' recent buy bias for Lupin Limited indicates strong confidence in the stock's future performance. This could encourage more investors to view Lupin Limited as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.